Elastagen is a Sidney, Australia-based clinical-stage medical company developing products based on a proprietary recombinant human tropoelastin platform technology. The company applies that platform to three main product areas: atrophic scars (including stretch marks and acne scars), derm-aesthetics, and tissue repair. Its lead programs include an intradermal tropoelastin implant to reduce the appearance of stretch marks, a skin-rejuvenation injectable to improve the skin’s physical properties, and a tropoelastin product to support repair of full-thickness skin wounds. Elastagen is set to initiate a clinical trial to evaluate the safety and efficacy of the intradermal implant for stretch marks. The wound-repair program has had support from the Wellcome Trust and the NSW Department of Health Medical Device Fund. The company closed an A$13M Series B to advance its lead products through clinical and commercial milestones.

Total raised

$9M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2016